Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

Becker’s Payer Issues Podcast

Becker’s Payer Issues Podcast artwork

AI-Driven, Personalized Care for Chronic Conditions and How Payers Are Adapting Through Digital Health Innovation

Apr 29, 202620 minAudio
ShareXLinkedInFacebookWhatsAppEmail

In this episode, Dr. Lisa Shah, Executive Vice President and Chief Medical Officer of Twin Health, discusses how AI-powered digital twin technology is transforming care for chronic conditions and enabling personalized, real-time interventions. She also shares insights on payer trends, outcomes-based models, and new approaches to reducing reliance on medications while improving long-term health outcomes. This episode is sponsored by Twin Health.

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Transcript

From the show. Tap a time to play from there.

Hi, everyone. This is Lucas Voss with Becker's Healthcare. Thanks so much for tuning in to the Becker's Healthcare podcast series. It's fantastic to have you. Today, we're talking about AI driven personalized care for chronic conditions and how payers are adapting through digital health innovation. And joining me for today's discussion, I'm so excited to have her, is doctor Lisa Shaw. She's the executive vice president and chief medical officer of Twin Health. Doctor Shaw, thanks so much for being here today. It's great to have you. Thank you, Lucas. It's wonderful to

be here. For those that might not know you yet at least, I do wanna start off with introductions. If you could just introduce yourself and just tell us a little bit about your work in health care. Yes. That's great. So, my name is doctor Shah, Lisa. I've been a I'm an internal medicine and pediatrics trained physician. I've been practicing for over twenty years now. Primarily now internal medicine, and we'll talk a little bit about what I do now. I did my training at the University of Chicago, and for the last, fifteen years, I've really

been focused on designing and implementing value based and and next generation models of care, particularly around chronic conditions and and chronic diseases. The work I do at Twin Health is very personal for me. We've been focused here on chronic metabolic diseases, and we'll talk a little bit about that today. But both my parents have type two diabetes and obesity, and Twin has really been the first time, you know, we we go into becoming a physician to help the people we love the most. It's been an incredible opportunity to really

see something change their lives. They were the first two patients on this program in the history of the program. And so, really doing great, reversed their diabetes, lost combined 45 pounds, and are off medication, and we'll talk a little bit about that today. When I started my career, I think one of the things I really struggled with was how impersonal medicine felt when I went into practice. Yeah. It you know, especially in primary care, it felt very much as I was giving generic advice

to people. You know, eat better, exercise more, stress less, sleep more, and then they look at me and go, thanks. Can I have a prescription? And that's really what was hard for me. And if you fast forward to where we are today, the opportunity to use artificial intelligence and machine learning, techniques and sensors, and we'll talk about how Twin does that today, with compassionate human care, has really made this hyper personalization,

continuous real time care possible so that people can actually, you know, fix the disruption in their bodies, fix this metabolic damage, not just manage a condition with a medication. Yeah. And I do wanna talk about those conditions a little bit more because I think they're at the core of some of the things that we're gonna touch on today in our conversation. Again, we we talk about, as you've mentioned, obesity and diabetes. Right? Unfortunately, those numbers are continuing to rise. We have made some inroads. We don't wanna ignore that, but they continue to rise. Right? And when we're

looking from the pair lens too, how are you seeing pairs respond there particularly when it comes to some of the digital innovation that you've just touched on? And then, again, what's gaining traction for you, and where are you seeing gaps still exist? Yeah. It's a great question. And, you know, I've had been working with payers for most of my career. And I think, you know, in this value based care world, we started with really traditional episodic care models and and point solutions. Right? And that was a great

start if you look back fifteen, twenty years ago, a solution for diabetes, a solution for heart disease, a solution for weight. But I think there's a growing recognition that those episodic and point solution, models are really not bending the cost curve enough, and they're not actually creating a place for long term sustained outcomes. So payers are, I think, moving away from that fragmented point solution, environment and landscape and really looking for two things,

models that, are continuous and and wrap around multiple conditions so that they're getting, you know, a lot of value for one, solution across all of these things that a that a patient is struggling with. And then we know these diseases do not travel alone. Obesity doesn't travel separately from diabetes. They're partnered as as is cardiac disease and some other diseases we'll talk about today, hypertension. And the second thing is I think they're really looking for payment models that are standing behind the outcomes and are outcomes based as

opposed to these traditional per member per month, you know, type of models where you're really paying, but there's no guarantee on the outcome. So those two things have been really what has, shifted, I think, in the in the payer landscape. I think the second thing is they're seeing cost go up in the world around things like medications, and utilization and prevalence. Right? So as you were saying, despite our best efforts, diabetes and obesity are growing. And

look at all the other conditions, metabolic associated fatty liver disease growing rapidly, the number one cause of liver transplants now in The US, right, and then globally. And so we're seeing these kinds of shifts, and and they're scratching our heads. We all are. So what do you what can you really do to shift this new standard of care or or create a new standard of care? And I think, metabolic health is now being seen as this continuous, suite of conditions that if we could really figure out how to target metabolism and metabolic health,

in a way that is very personalized because it's unique for everyone, there is an opportunity to really prevent, both of the rising costs and the long term health op, complications. And I think in order to do that, the traction we're seeing is really with solutions that are data driven. They're taking multiple real time datasets and personalizing the engagement for the individual to something that the person is willing to do and can do, that is also overseen by a clinical care

team, particularly for areas like diabetes and and weight. You mentioned something very critical there with with just the member engagement piece, which is so crucial because, again, it doesn't work if the member doesn't engage. If there's no engagement, then there's no solution really. You talk about the concept of, a digital twin. Can you walk us through what that experience looked like, what that is for members, and how it differs from sort of the traditional

digital health approach that we're seeing a lot around health care today? Yes. Yeah. It's a great question. So digital twins have been around for a long time. Twin, Twin Health did not create, the first digital twin concept, though we are the first, application of digital twin technology to human metabolism. But digital twins are really they're similar technology being used in other

self driving, autonomous driving cars, have digital twins. And, essentially, when you think of a very complex system like self driving cars or aviation or human metabolism, arguably the most complicated system, in the world. The, ability to use sensor technology, which we've really evolved with here in health care right now and in in human body wearables. But the the cars, for instance, put sensors on the outside of the car and the

inside. And each driver is unique, but so is the external environment where the car is. Right? Whether you're in a traffic jam or you're driving through snowy mountains or on a beach. So the ability to really predict using sensor technology that gets smarter with every drive and every, exposure to predict bad things before they happen is really what a digital twin system is trying to do, and then making improvements before those bad things happen, based on what it's seeing through all the

sensor data. In metabolism, we're doing the same thing. So we essentially create an AI digital twin of every Twin Health member that evolves and learns every day and really pays attention to clinical data that the sensors are collecting. So think about those as the inside of the car or inside the human. Right? So my blood pressure, my blood sugar, my heart rate, my stress levels, my sleep data that we're

getting from all of these wearables. And then it's also looking at the outside. So think of the environment where the car is driving, the choices a person is making. So am I choosing to eat at McDonald's? Am I choosing to, sleep during the daytime because I have a night shift job? And so when it looks at all of those things, whether controllable in the person's life or not, but the reality of their life, it puts the two together and creates models that can help improve those clinical data points

with environmental, lifestyle suggestions that the member is willing and able to do. That's the key, willing and able to do. Because if they're not, we've seen this before. We've seen keto diets. We've seen, you know, extreme gym programs, and they work for a few months and then people stop because they're just not really sustainable. I like to think that my extreme gym program would work for a month. It works for about a week. So I completely understand. It's very, very important.

I agree. Again, we come back to the engagement piece. Now the great thing is you've touched on the fact that data is so, so critical. And you announced results from a randomized controlled trial with Cleveland Clinic, and it was published in the New England Journal of Medicine Catalyst. I'd love to talk a little bit about that because I think that data is really crucial to what we're talking about today. At a high level, can you outline some of those key findings and sort of how they shape the broader conversation about some of the things that you've touched on specifically when we think about AI

driven personalized care? Yeah. Yes. Absolutely. So the Cleveland Clinic study that we did was very intentional. We really wanted to demonstrate you know, we see a lot of randomized controlled trials looking at medications. We don't see a lot of randomized controlled trials where we can actually use, AI digital twin technology, lifestyle changes, and actually eliminate medications, which is really what twin does with this AI digital twin model. It gets people off medications. It reduces their a one c.

It reduces their weight. They lose weight in a healthy way, which we'll talk a little bit more about, later. But it also is, healing a lot of different aspects of their metabolism and their pathways in their body. So in this study, we wanted to demonstrate that versus usual care for people living with type two diabetes, the AI digital twin intervention was superior. And, we randomized people to either usual care at the Cleveland Clinic or the AI digital twin. Cleveland Clinic ran

the study. The investigators did all of the randomization and consenting. 100 people were randomized into the intervention arm. And what we found is, that seventy one percent of the people who were in the intervention arm normalized their a one c and got off all of their medications except metformin, which is sort of a standard baseline, compared to only two percent in the control group. So seventy one percent of the intervention arm at one year had an a one c that reduced below 6.5, which is a

non type two diabetes a one c and were off their high cost medication, all medications actually other than the metformin versus two percent in the control group. We also found sixty six percent of participants normalized their hypertension. Eighty five percent of them eliminated the GLP one medications and sustained weight loss. Not only that, but they saw 27 pounds average weight loss that they kept off versus 12 pounds in the usual care group. So we not only took away this, you

know, drug, the GLP ones, which I'm sure we'll cover later, but they also were able to lose more weight, and it was healthy weight with an increase in muscle mass, which, you know, is is a really important aspect of, having a healthy lifestyle is making sure that that weight loss is is a healthy weight loss. So the study really represented a turning point in diabetes and metabolic diseases because not only did we show what we could do for diabetes, but we showed what we were doing across a host of metabolic conditions,

including metabolic associated fatty liver disease. And it offers the strongest evidence to date that AI digital twin technology can really actually impact and fix disrupted dysfunctional metabolism without adding and actually with eliminating expensive costly medications that have many side effects. And just to come back to your earlier point, I feel like this data is also so important because, again, then providers can go beyond what you've mentioned earlier, which is this generalized experience of, like, eat healthier, sleep better, which

doesn't really help. This data backs some of those more precise approaches up, which is so, so crucial. You touched on GLP ones, and I do wanna spend just a little bit of time on that. We could spend a whole episode talking about it, really, in this context specifically. But they, again, they continue to create both opportunity, but also strain for health plans and employers. Right? There's there's cost, long term adherence, some of those things. Right? When you're thinking about GLP ones in the context of your work, certainly, but also overall,

what shifts do you think are needed, and how are you positioning Twin Health, right, within this evolving landscape? What what's most exciting for you there? Yes. So I really appreciate it. Lucas, look, I, you know, I wanna be, clear. I think GLP ones are an incredible advancement in health care and in science, and medications play a really, really critical role in managing metabolic disease. And when they're clinically appropriately used, they can absolutely help stabilize, disease progression,

improve disease progression, manage the disease, and help with early progress. But I have a statement I love to say, which is GLP ones are not for everyone, and they're not forever. And I think what's really important is understanding that these medications also have a lot of side effects. You know, from the hair loss to the nausea and the GI, issues that people experience to even just, you know, a lot of my patients tell me this apathy toward food and toward sharing and, you know, breaking bread,

so to speak, with their families. And, you can also see pancreatitis, hospitalization. So there's there's a lot to consider, and we need to have a solution for people who either don't want to take and now there are orals, but there are many injectables of these medications, who don't wanna take these medications for life or really don't even wanna start them, want to try to figure out a way to be medication free. And so I think it's really important to have solutions that do that. The other problem is that if you look at the history of diabetes

medications, they're not actually fixing the disrupted metabolism. They're not actually fixing insulin resistance, and some of these things that are at the precursor to the conditions that are surfacing, with, you know, the clinical metrics that we see or clinical data. So Twin uses medications as one tool, but what we are really doing is helping our clinicians and patients or members understand their own personal biology. Watching their app every day and saying, wow.

My digital twin just said that when I eat rice, I have this response. But when I eat bread, I have a very different response. Mhmm. And, you know, this is something we see in couples and partners who use our program. That one person to the next, you could be living in the same house, but you have a very different personalized response to the food you consume, the order in which you eat the foods on your plate, and whether you slept well last night, your stress level, or whether you went for a walk this morning with the dog or your son or

daughter took the dog out. So people have a completely different response to the same exact food just based on what's happening in their lives. And this is, I think, something that medications don't really crack the nut on. And if you want a world where people can have no side effects, can really fix the underlying problem, they have to understand their personal body. They have to understand what's precise and what's meaningful to their health, to their blood sugar, their weight gain, their stress levels, their sleep.

So we really use that AI digital twin to to monitor that and give precise recommendations real time using that sensor data and member preferences to the member every single day. And that's what managing your diseases is really about. It's about daily iteration. Right? If you go on vacation for a week and then you come back, you wanna get back on track and you can do that if daily you understand or have insights into your own body, and that's what we're really shifting the paradigm on in metabolic care.

We're really allowing people this chance to say, well, I took a GLP one, but I'm I'm done with it, or I've plateaued, and I'm not responding anymore, but I'm so terrified to get off because I hear about this rebound waking, and I don't wanna be back where I am. So is there a solution that can help me responsibly have this medication, improve my health holistically, and give me an opportunity to get off of it? And is there a solution for people who don't even want to start? And

that is, for me, really exciting. I mean, my personal, hope is that people have choice. And I think, health care today isn't set up to give people choice in their health, and Twin really gives that to people. I want the med, but only for a short time, and then I want to get off of it. And that's that's totally reasonable. And I I think it's important to have more and more solutions that can support that. Yeah. I'm so glad that you mentioned that because, again, we touched on the engagement earlier

in the conversation. But, again, that aspect of giving somebody agency is truly what then enables them thinking, okay. I can make a change here. I can do this together, which is so crucial. I'm so glad that you've mentioned that. It's it's very, very critical. Doctor Shah, it's so fantastic to have you on. Thank you so much for taking some time for us. Anything else that you think deserves a little bit more attention that we haven't touched on in our conversation here? Just wanna turn the floor over to you. Great. Well, thank you. Well, I'll just leave you with one thing. I mean, we talk a lot about AI in health care,

and I know it's everywhere, you know, and I I see it everywhere. But most of the talk about AI is how do we make health care systems and people more efficient. Coding, you know, how do we get them to document more efficiently? How do we make providers, you know, able to do their jobs better, prior authorizations? Twin is doing all of that absolutely with our care teams, but we're doing it to reengineer metabolism. We're using AI to really improve how people understand their own health,

how they can address the things they struggle with every single day and redefining how we could solve chronic disease and redefining the standard of care with AI digital twin. So I think it's really exciting, and I I hope we can see more progress on using AI toward the diseases and toward the conditions, as well in the future. Doctor Shah, so great to have you. Thanks so much for being here. You as well. Thank you for having me. We also want to thank our podcast sponsor, Twin Health. You can tune in to more podcasts from Becker's

Healthcare visiting our podcast page at beckershospitalreview.com.

Open the transcript file

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. Payment Integrity Can Protect Savings Without Creating More Friction

    Nov 20, 202619 minAudio

    In this episode, Jon Grandstaff, Senior Vice President of Payment Integrity at Zelis, discusses how payers can reduce payment friction, use AI to support more accurate claims reviews and improve payer-provider...

    Credit the people on this episode

  2. From Learning Collaborative to Gap Closure: How Wisconsin Medicaid Is Telethinking Colorectal Cancer Screening

    Nov 19, 202612 minAudio

    In this episode, Amy Conlon, MPH, Population Health Sr. Manager at Exact Sciences, and Jeff Huebner, MD, FAAFP, Executive Medical Officer, Division of Medicaid Services, Wisconsin Department of Health Services, discuss...

    Credit the people on this episode

  3. What Health Plans Miss When They Look at Markets in Isolation

    Nov 18, 202617 minAudio

    In this episode, Denis Mrkva, Senior Vice President of Analytics Solutions at Data Axle, discusses how health plans can combine consumer, employer, geographic and healthcare data to identify growth opportunities, reduce...

    Credit the people on this episode

  4. Strengthening Provider Networks Through AI, Data and Strategic Partnerships

    Nov 17, 20268 minAudio

    In this episode, Bob Tavernier, Solutions Executive at Quest Analytics®, discusses how health plans can leverage AI, provider data and strategic partnerships to improve network accuracy, strengthen regulatory compliance...

    Credit the people on this episode

  5. Martina Lee Strickland, Head of Marketing, PR and Brand at Clever Care Health Plan

    Nov 16, 202617 minAudio

    In this episode, Martina Lee Strickland, Head of Marketing, PR and Brand at Clever Care Health Plan, joins the podcast to discuss the importance of building trust when serving underserved communities. She also shares...

    Credit the people on this episode